XNAS · BCAB
+4.09% · +$0.1300 · Vol Not reported
Pre-market · updated 06:13:54 ET
BioAtla, Inc. Common Stock

BioAtla, Inc. Common Stock

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
$3.31
Card
Relationship Map

Veridion Score

BETALOW CONF · 4/6 factorsMethodology
Earnings absence reason unknown · Sentiment absence reason unknown
BCAB
BioAtla, Inc. Common Stock
Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

65/ 100
Veridion Score
BUY BIAS · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4/6 factors with data · Fri Aug 21 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is BCAB moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading BCAB catalysts
About BioAtla, Inc. Common Stock
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2020
Employees
41
Country
US

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$3.18
Last session
Day high
$3.18
Last session
Day low
$3.18
Last session
Previous close
$3.18
52W high
$61.00
-94.57% from high
52W low
$3.06
0% of range
Market cap
$5.3M
EPS
$-4.5400
Beta
1.22
Shares out
1.7M
Avg volume
52.6K
VWAP
$3.18
Last session
Price history computed in-house
1W
+8.17%
1M
-1.78%
3M
-15.35%
1Y
-81.41%
YTD
-88.34%
SMA 50 $3.60 · below
SMA 200 $13.54 · below
52W position 0%

BCAB overview

Veridion Score
65
Registered · 2026-08-21
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around BCAB.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading BCAB Form 4 filings
Public disclosures

Congress activity in BCAB

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for BCAB in the cached public ledger.

Federal contracts

BCAB contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for BCAB in this window.
Lobbying spend

BCAB lobbying filings, year to date.

Registered lobbying filings matched to BioAtla, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for BCAB in this window.
Loading news for BCAB
Analyst ratings
Sovereign unlock shows live analyst consensus for BCAB.
Options
Sovereign unlock shows live options positioning for BCAB.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.